CervoMed (CRVO) Director Granted 8,100 Stock Options at $6.52

CervoMed Inc. (CRVO) Form 4 filing discloses an initial equity grant to newly elected non-employee director Dr. Marwan Sabbagh.

Rhea-AI Filing Summary

CervoMed Inc. (CRVO) Form 4 filing discloses an initial equity grant to newly elected non-employee director Dr. Marwan Sabbagh. On 06/23/2025 he received a stock option for 8,100 common shares at an exercise price of $6.52 under the 2025 Equity Incentive Plan. The option vests in equal 1/12-increments on the last day of each month from 06/30/2025 through 05/31/2026, contingent on continued board service, and expires on 06/23/2035. No common shares were purchased or sold, and total derivative holdings now stand at 8,100 options. The transaction is routine director compensation with negligible dilution and no immediate impact on CervoMed’s financial position.

Insights

Corporate Governance Expert

TL;DR – Routine option grant aligns new director with shareholders; immaterial to capital structure, neutral for valuation.

The Form 4 records a standard non-employee director award: 8,100 options at $6.52, vesting monthly over one year. Such grants are customary for small-cap biotech boards and are designed to align governance incentives without requiring cash outlay. The size represents a tiny fraction of CervoMed’s outstanding shares, resulting in de minimis dilution and no earnings effect. Because no shares were bought or sold, insider sentiment cannot be inferred. Overall, the filing is administrative and should not materially influence investment decisions.

Insider Trade Summary

Grant/Award: 8,100 shares

Grant/Award 1 txn

Insider Sabbagh Marwan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,100	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 8,100 contracts (Direct)

Footnotes (1)

1. F1. On June 23, 2025, in connection with the Reporting Person's election to the Issuer's board of directors at its 2025 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,100 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

FAQ

What insider transaction did CervoMed (CRVO) report on 06/23/2025?

A grant of 8,100 stock options to new director Dr. Marwan Sabbagh under the 2025 Equity Incentive Plan.

What is the exercise price and expiration date of the granted options?

The options carry a $6.52 exercise price and expire on 06/23/2035.

How does the vesting schedule work for these CRVO options?

They vest monthly in 1/12-increments on the last day of each month starting 06/30/2025, completing after one year.

Did the director buy or sell any CervoMed common stock?

No. The Form 4 shows only an option grant; no common shares were bought or sold.

Does this Form 4 filing materially affect CervoMed’s share count?

The 8,100-option grant represents immaterial dilution relative to the company’s outstanding shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2025 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabbagh Marwan

(Last) (First) (Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.52	06/23/2025		A		8,100		(1)	06/23/2035	Common Stock	8,100	$0	8,100	D

Explanation of Responses:

1. On June 23, 2025, in connection with the Reporting Person's election to the Issuer's board of directors at its 2025 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,100 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.